EGFR and skin squamous cell carcinoma: Second, the efficacy of cetuximab is restricted to patients with high EGFR expression (IHC score ≥2+), yet only 60% of cSCC patients exhibit such expression levels (84), with an objective response rate (ORR) of merely 20%–30% (85).